Meeting
2020 ASCO Virtual Scientific Program
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
Authors
Paul Bernard Romesser
Memorial Sloan Kettering Cancer Center, New York, NY
Paul Bernard Romesser , Emma B. Holliday , Tony Philip , Barbara Sarholz , Mirjam Kuipers , Almudena Rodriguez-Gutierrez , Ivan Diaz-Padilla , Eric David Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03770689
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4117)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4117
Abstract #
TPS4117
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
First Author: Paul Bernard Romesser
Poster
2015 Gastrointestinal Cancers Symposium
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
First Author: Brian G. Czito
Poster
2014 ASCO Annual Meeting
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
First Author: Brian G. Czito
Poster
2023 ASCO Annual Meeting
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.
First Author: Michael Michael